Protagonist Therapeutics Inc(PTGX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PTGX Protagonist Therapeutics Inc

盘后交易 11-14 16:25:26 EST

41.04

-1.63

-3.82%

盘后41.04

+0.000.00%

16:08 EST

最高43.14	最低40.91	成交量61.77万
今开42.67	昨收42.67	日振幅5.23%
总市值24.46亿	流通市值18.21亿	总股本5,960万
成交额2,556万	换手率1.39%	流通股本4,438万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PTGX","market":"US","secType":"STK","nameCN":"Protagonist Therapeutics Inc","latestPrice":41.04,"timestamp":1731618000000,"preClose":42.67,"halted":0,"volume":617717,"hourTrading":{"tag":"盘后","latestPrice":41.04,"preClose":41.04,"latestTime":"16:08 EST","volume":22278,"amount":914289.12,"timestamp":1731618531377},"delay":0,"floatShares":44378221,"shares":59598018,"eps":2.683365,"marketStatus":"盘后交易","marketStatusCode":4,"change":-1.63,"latestTime":"11-14 16:25:26 EST","open":42.67,"high":43.14,"low":40.91,"amount":25558961.27333,"amplitude":0.052262,"askPrice":41.84,"askSize":40,"bidPrice":40.24,"bidSize":9,"shortable":3,"etf":0,"ttmEps":2.683365,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1731632400000},"adr":0,"listingDate":1470888000000,"adjPreClose":42.67,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":43.7,"preClose":42.67,"latestTime":"07:05 EST","volume":105,"amount":4580.3502149999995,"timestamp":1731585930808},"postHourTrading":{"tag":"盘后","latestPrice":41.04,"preClose":41.04,"latestTime":"16:08 EST","volume":22278,"amount":914289.12,"timestamp":1731618531377},"volumeRatio":1.059166,"impliedVol":0.8871,"impliedVolPercentile":0.9722},"requestUrl":"/m/hq/s/PTGX/wiki","defaultTab":"wiki","newsList":[{"id":"2482734541","title":"Protagonist Therapeutics, Inc.2024财年第三财季实现净利润-33.21百万美元，同比增加2.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482734541","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482734541?lang=zh_cn&edition=full","pubTime":"2024-11-12 00:00","pubTimestamp":1731340829,"startTime":"0","endTime":"0","summary":"11月12日，Protagonist Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-33.21百万美元，同比增加2.64%；其中营业收入为4.68百万美元，每股基本收益为-0.54美元。从资产负债表来看，Protagonist Therapeutics, Inc.总负债71.94百万美元，其中短期债务45000.00美元，资产负债比为0.09，流动比率为0.11。机构评级：截至2024年11月12日，当前有8家机构对Protagonist Therapeutics, Inc.目标价做出预测，其中目标均价为54.38美元，其中最低目标价为43.00美元，最高目标价为65.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112000038a22d0d7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112000038a22d0d7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTGX"],"gpt_icon":0},{"id":"2481541559","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481541559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481541559?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Cigna、万豪和 Ralph Lauren。要闻             * Cigna   ：Piper Sandler将目标价从392美元上调至394美元             * 万豪  ：杰富瑞将目标价从 225 美元上调至 251 美元              * Ralph Lauren Corp   ：TD Cowen 将目标价从 208 美元上调至 251 美元              * Vertex Pharmaceuticals Inc   ：丰业银行将目标价从480美元上调至486美元             * Wynn Resorts Ltd   ：摩根大通将目标价从101美元上调至113美元  以下是路透周二报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","MDGL","ARES","EDIT","CSTL","LU0949170772.SGD","INSP","LU0971096721.USD","EVER","OMI","CMS","AMG","MAR","LU0149725797.USD","LU0320765489.SGD","HIMS","BWIN","SHAK","ST","BEN","LU1363072403.SGD","ATUS","RL","PTGX","NYT","KROS","BMRN","ILMN","SM","IE00BZ1G4Q59.USD","GKOS","LSCC","LU1489326972.SGD","BK4106","LU1244550221.USD","AWI","EGHT","FRPT","SLAB","RZLT","CI","LU0266512127.USD","FIS","LU","NMRA","CAMP","FOXA"],"gpt_icon":1},{"id":"2481415545","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481415545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481415545?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Cigna、万豪和 Ralph Lauren。要闻             * Cigna   ：Piper Sandler将目标价从392美元上调至394美元             * 万豪  ：杰富瑞将目标价从 225 美元上调至 251 美元              * Ralph Lauren Corp   ：TD Cowen 将目标价从 208 美元上调至 251 美元              * Vertex Pharmaceuticals Inc   ：丰业银行将目标价从480美元上调至486美元             * Wynn Resorts Ltd   ：摩根大通将目标价从101美元上调至113美元  以下是路透周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSCC","LU1363072403.SGD","CSTL","BK4106","CAMP","EGHT","LU0320765489.SGD","FIS","SHAK","ST","CMS","IE00BZ1G4Q59.USD","LU0971096721.USD","GKOS","ILMN","OMI","LU0949170772.SGD","CI","ARES","EVER","SM","AWI","IRON","MAR","LU1244550221.USD","LU0266512127.USD","LU","ATUS","FRPT","NYT","BEN","LU1489326972.SGD","EDIT","BWIN","RZLT","LU0149725797.USD","FOXA","RL","INSP","NMRA","KROS","AMG","PTGX","SLAB","BMRN","MDGL"],"gpt_icon":1},{"id":"2480381801","title":"Protagonist Therapeutics Inc    预计每股亏损 62 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2480381801","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480381801?lang=zh_cn&edition=full","pubTime":"2024-11-02 12:08","pubTimestamp":1730520482,"startTime":"0","endTime":"0","summary":"   * Protagonist Therapeutics Inc    预计将在11月4日公布截至2024年9月30日的业绩报告()，季度收入将有所增长。* 根据LSEG的数据，6位分析师的平均预期显示，这家总部位于加利福尼亚州纽瓦克市的公司预计将实现营收166.7万美元。* LSEG 分析师对 Protagonist Therapeutics Inc 的平均预期是每股亏损 62 美分。* 华尔街对 Protagonist Therapeutics Inc 的 12 个月目标价中位数为 51.50 美元，高于其最新收盘价 46.76 美元。11月2日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","LENZ"],"gpt_icon":0},{"id":"2479748364","title":"Protagonist Therapeutics Inc    预计每股亏损 60 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2479748364","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479748364?lang=zh_cn&edition=full","pubTime":"2024-10-31 11:30","pubTimestamp":1730345445,"startTime":"0","endTime":"0","summary":"   * Protagonist Therapeutics Inc    预计将在11月1日公布截至2024年9月30日的业绩报告()，季度收入将有所增长。* 根据 LSEG 的数据，7 位分析师的平均预期显示，这家总部位于加利福尼亚州纽瓦克市的公司预计将实现收入 214.3 万美元。* LSEG 分析师对 Protagonist Therapeutics Inc 的平均预期是每股亏损 60 美分。* 华尔街对 Protagonist Therapeutics Inc 的 12 个月目标价中位数为 51.00 美元，高于其上次收盘价 47.62 美元。10月31日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","PTGX"],"gpt_icon":0},{"id":"2458590066","title":"Protagonist Therapeutics, Inc.盘中异动 早盘股价大涨5.04%报39.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458590066","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458590066?lang=zh_cn&edition=full","pubTime":"2024-08-09 23:19","pubTimestamp":1723216776,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日23时19分，Protagonist Therapeutics, Inc.股票出现异动，股价快速拉升5.04%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.50%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809231936941ffc3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809231936941ffc3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","PTGX"],"gpt_icon":0},{"id":"2457841211","title":"Protagonist Therapeutics, Inc.盘中异动 早盘股价大涨5.91%报38.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457841211","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457841211?lang=zh_cn&edition=full","pubTime":"2024-08-07 21:43","pubTimestamp":1723038190,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日21时43分，Protagonist Therapeutics, Inc.股票出现波动，股价大幅上涨5.91%。截至发稿，该股报38.35美元/股，成交量4.4292万股，换手率0.08%，振幅4.92%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807214311af96692f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807214311af96692f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PTGX","LENZ"],"gpt_icon":0},{"id":"2456269758","title":"Protagonist Therapeutics Inc    预计每股亏损 60 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2456269758","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456269758?lang=zh_cn&edition=full","pubTime":"2024-08-03 06:15","pubTimestamp":1722636915,"startTime":"0","endTime":"0","summary":"   * Protagonist Therapeutics Inc    预计在8月5日公布截至2024年6月30日的业绩时，季度收入将有所增长(预计)。* 根据LSEG的数据，5位分析师的平均预期显示，这家总部位于加利福尼亚州纽瓦克市的公司预计将实现800万美元的营收。* LSEG 分析师对 Protagonist Therapeutics Inc 的平均预期是每股亏损 60 美分。* 华尔街对 Protagonist Therapeutics Inc 的 12 个月目标价中位数为 48.00 美元，高于其上一次收盘价 37.36 美元。8月2日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","LENZ"],"gpt_icon":0},{"id":"2456891282","title":"Protagonist Therapeutics, Inc.盘中异动 早盘股价大跌5.72%报35.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456891282","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456891282?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:31","pubTimestamp":1722605487,"startTime":"0","endTime":"0","summary":"北京时间2024年08月02日21时31分，Protagonist Therapeutics, Inc.股票出现异动，股价急速下挫5.72%。截至发稿，该股报35.79美元/股，成交量7687股，换手率0.01%，振幅0.18%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.74%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802213127941fd893&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802213127941fd893&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTGX","BK4139","LENZ"],"gpt_icon":0},{"id":"2455995775","title":"Protagonist Therapeutics Inc    预计每股亏损 60 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455995775","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455995775?lang=zh_cn&edition=full","pubTime":"2024-07-31 04:41","pubTimestamp":1722372104,"startTime":"0","endTime":"0","summary":"   * Protagonist Therapeutics Inc    预计在8月1日公布截至2024年6月30日的业绩报告时，季度收入将有所增长(预计)。* 根据LSEG的数据，5位分析师的平均预期显示，这家总部位于加利福尼亚州纽瓦克市的公司预计将实现800万美元的营收。* LSEG 分析师对 Protagonist Therapeutics Inc 的平均预期是每股亏损 60 美分。* 华尔街对 Protagonist Therapeutics Inc 的 12 个月目标价中位数为 48.00 美元，高于上一交易日的收盘价 38.81 美元。7月30日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","LENZ"],"gpt_icon":0},{"id":"2454872666","title":"小摩：维持Protagonist Therapeutics(PTGX.US)评级，由增持调整至增持评级, 目标价由39.00美元调整至48.","url":"https://stock-news.laohu8.com/highlight/detail?id=2454872666","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454872666?lang=zh_cn&edition=full","pubTime":"2024-07-25 22:07","pubTimestamp":1721916474,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0211326839.USD","LU1119994496.HKD","BK4588","LU1084165304.USD","LU1363072403.SGD","LU1032466523.USD","LU0882574139.USD","LU0976567544.SGD","BK4207","IE00BLSP4239.USD","LU0320765646.SGD","BK4585","IE00BBT3K403.USD","BK4504","IE00BLSP4452.SGD","LU0211331839.USD","LU1244550577.SGD","LU0149725797.USD","IE00B1XK9C88.USD","IE0034235188.USD","LU1914381329.SGD","LU1894683348.USD","BK4581","IE000M9KFDE8.USD","LU1267930490.SGD","BK4534","LU0106831901.USD","IE00BHPRN162.USD","LU1894683264.USD","BK4533","IE00BFXG1179.USD","LENZ","LU0267386448.USD","LU1261432733.SGD","BK4516","IE00B1BXHZ80.USD","LU1668664300.SGD","LU1670627923.USD","LU0234572021.USD","BK4566","PTGX","LU1244550221.USD","IE00BJTD4N35.SGD","LU0417517546.SGD","LU","LU1244550494.USD","LU0971096721.USD","IE00B3S45H60.SGD","LU0310799852.SGD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2454812044","title":"美国研究综述-爱德华生命科学公司、国民银行控股公司、赛捷治疗公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2454812044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454812044?lang=zh_cn&edition=full","pubTime":"2024-07-25 15:21","pubTimestamp":1721892117,"startTime":"0","endTime":"0","summary":"    路透7月25日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括爱德华生命科学公司、国民银行控股公司和赛捷治疗公司。要点             * 爱德华生命科学公司  ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0187121727.USD","FCF","HNVR","GEV","EW","BK4023","T","EBMT","MC","CCS","PFSI","ODFL","EL","FOR","LU1121112475.USD","NAVI","CASH","IPG","CME","LU","NBBK","EQT","PRG","SAGE","LU1119994496.HKD","PB","ITW","CCK","CFFN","LU1974910355.USD","FSBW","KNX","PM","FI","PT","ALGN","LW","DV","GSHD","PTGX","HCA","NBHC","PHM","PPBI","CYH","BSX"],"gpt_icon":1},{"id":"2454897339","title":"Protagonist Therapeutics Inc: JP Morgan将目标价从39美元上调至48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454897339","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454897339?lang=zh_cn&edition=full","pubTime":"2024-07-25 12:28","pubTimestamp":1721881700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0314104364.USD","LU1162221912.USD","LU1074936037.SGD","IE00BZ1G4Q59.USD","LU1363072403.SGD","LU0098860793.USD","LU0267386448.USD","LU0320765646.SGD","LU1668664300.SGD","PTGX","LU1989772840.SGD","BK4585","LU1989772923.USD","BK4504","LU0106831901.USD","BK4139","BK4588","BK4127","IE00BKVL7J92.USD","BK4534","LU0971096721.USD","BK4581","LENZ"],"gpt_icon":0},{"id":"2453900096","title":"BTIG：维持Protagonist Therapeutics(PTGX.US)评级，由买入调整至买入评级, 目标价由41.","url":"https://stock-news.laohu8.com/highlight/detail?id=2453900096","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453900096?lang=zh_cn&edition=full","pubTime":"2024-07-24 21:32","pubTimestamp":1721827976,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","PTGX","BK4139"],"gpt_icon":0},{"id":"2453021882","title":"美国研究综述-Alphabet、通用电气航空航天、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2453021882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453021882?lang=zh_cn&edition=full","pubTime":"2024-07-24 15:28","pubTimestamp":1721806095,"startTime":"0","endTime":"0","summary":"    路透7月24日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 Alphabet、通用电气航空和特斯拉。股票条目按字母顺序排列。* A of Smith Corp   ：杰富瑞将目标价从90美元下调至85美元             * A of Smith Corp   ：Stifel将其评级从 \"持有 \"上调至 \"买入\"，目标价从97美元上调至98美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KREF","LU1989763690.USD","AVY","AOS","BOKF","EIX","PHM","CALX","LU2244417387.USD","LU2108987350.USD","CLF","SLG","PCAR","PII","HTLD","CSGP","TSLA","BRO","KMB","IE00BKPKM429.USD","PMT","EFSC","ALK","BK4173","DHR","GE","MANH","MEDP","SHW","HCA","IVZ","LU0211331839.USD","PTGX","GOOG","GPC","GOOGL","COF","LU1989763427.SGD","ENVA","PFSI","TSLL","SVV","MTDR","RRR","CMCSA","IE00BJLML261.HKD","EWBC"],"gpt_icon":1},{"id":"2453052619","title":"Protagonist Therapeutics, Inc.盘中异动 股价大涨5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453052619","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453052619?lang=zh_cn&edition=full","pubTime":"2024-07-23 23:54","pubTimestamp":1721750095,"startTime":"0","endTime":"0","summary":"北京时间2024年07月23日23时54分，Protagonist Therapeutics, Inc.股票出现异动，股价急速拉升5.43%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.10%。其相关个股中，Azitra Inc、Salarius Pharmaceuticals, Inc.、Adial Pharmaceuticals, Inc涨幅较大，Salarius Pharmaceuticals, Inc.、Azitra Inc、Adial Pharmaceuticals, Inc较为活跃，换手率分别为7159.59%、5424.66%、3430.85%，振幅较大的相关个股有Salarius Pharmaceuticals, Inc.、Azitra Inc、Adial Pharmaceuticals, Inc，振幅分别为366.13%、365.43%、137.74%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723235455af93adf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723235455af93adf0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","PTGX"],"gpt_icon":0},{"id":"2449470378","title":"Protagonist Therapeutics, Inc.盘中异动 急速上涨5.78%报35.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449470378","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449470378?lang=zh_cn&edition=full","pubTime":"2024-07-08 21:37","pubTimestamp":1720445836,"startTime":"0","endTime":"0","summary":"北京时间2024年07月08日21时37分，Protagonist Therapeutics, Inc.股票出现异动，股价大幅上涨5.78%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708213716941f4ebe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708213716941f4ebe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTGX","BK4139","LENZ"],"gpt_icon":0},{"id":"2446143505","title":"BUZZ-Protagonist Therapeutics 在标准普尔小型股指数中跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2446143505","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446143505?lang=zh_cn&edition=full","pubTime":"2024-06-28 19:41","pubTimestamp":1719574898,"startTime":"0","endTime":"0","summary":"    6月28日 - ** Protagonist Therapeutics  股价盘前上涨10.3%至35.16美元，创两周新高，该公司将于下周加入标准普尔小型股600指数<.SPCY** 据标准普尔道琼斯指数公司称，生物技术公司将在 7 月 3 日周一开盘前取代  Encore Wire    加入标准普尔小型股 600 指数<.SPCY** 意大利电缆制造商普睿司曼  以42亿美元的价格收购了 。** PTGX的主要候选产品 ，包括用于治疗一种罕见血液病的rusfertide和与强生  合作开发的银屑病药物JNJ-2113。** 截至本周四收盘，PTGX 的股价累计上涨了 39%，公司市值达到约 19 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875086.SGD","PTGX","BK4096","LU0234572021.USD","LU0912757837.SGD","LU2133065610.SGD","BK4581","SG9999002232.USD","LENZ","LU1196500208.SGD","LU1221951129.SGD","LU1732800096.USD","IE00B1BXHZ80.USD","JNJ","BUZZ","LU1023059063.AUD","LU1057294990.SGD","LU1244550577.SGD","BK4504","BK4550","LU0640476718.USD","BK4585","LU1032955483.USD","LU1244550494.USD","LU1430594728.SGD","LU0320765646.SGD","LU0792757196.USD","LU1162221912.USD","LU1585245621.USD","LU0122379950.USD","WIRE","LU1059921491.USD","LU1261432733.SGD","LU1267930813.SGD","SG9999002224.SGD","IE00B19Z3B42.SGD","LU1066051498.USD","LU2347655156.SGD","BK4588","BK4592","IE00B19Z3581.USD","SG9999001440.SGD","LU2468319806.SGD","BK4139","IE0002270589.USD","IE00BSNM7G36.USD","LU1732799900.SGD","BK4568","LU1280957306.USD","LU1032466523.USD"],"gpt_icon":0},{"id":"2442557846","title":"Protagonist Therapeutics, Inc.盘中异动 股价大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442557846","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442557846?lang=zh_cn&edition=full","pubTime":"2024-06-12 21:32","pubTimestamp":1718199139,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日21时32分，Protagonist Therapeutics, Inc.股票出现异动，股价急速上涨5.39%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213219941ee0c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213219941ee0c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","PTGX"],"gpt_icon":0},{"id":"2442504847","title":"Protagonist Therapeutics, Inc.盘中异动 股价大跌5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442504847","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442504847?lang=zh_cn&edition=full","pubTime":"2024-06-10 21:45","pubTimestamp":1718027123,"startTime":"0","endTime":"0","summary":"北京时间2024年06月10日21时45分，Protagonist Therapeutics, Inc.股票出现波动，股价急速下跌5.43%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.53%。消息层面，截至21时45分，《Form 144 | Protagonist Therapeutics关联方拟出售3.5万股股份，价值约118.02万美元》资讯为影响Protagonist Therapeutics, Inc.的重要信息。该信息摘要如下：根据美国证券交易委员会美东时间6月7日披露的文件，$Protagonist Therapeutics $关联方Dinesh Patel拟于6月7日出售3.5万股普通股股份，总市值约118.02万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240610214524941ed69e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240610214524941ed69e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTGX","BK4139","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protagonist-inc.com","stockEarnings":[{"period":"1week","weight":-0.1036},{"period":"1month","weight":-0.0794},{"period":"3month","weight":0.0512},{"period":"6month","weight":0.3881},{"period":"1year","weight":1.5908},{"period":"ytd","weight":0.8609}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.022},{"period":"3month","weight":0.0798},{"period":"6month","weight":0.1279},{"period":"1year","weight":0.3308},{"period":"ytd","weight":0.2564}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Protagonist Therapeutics, Inc.在特拉华州注册成立于2006年8月22日，总部位于加利福尼亚州米尔皮塔斯。该公司是一家生物制药公司，其基于多肽的新化学实体rusfertide和JNJ-2113（原名PN-235）处于不同的开发阶段，均源自专有的发现技术平台。该公司的临床项目分为两大类疾病：（一）血液学和血液疾病，以及（二）炎症和免疫调节疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.049238},{"month":2,"riseRate":0.5,"avgChangeRate":-0.008856},{"month":3,"riseRate":0.375,"avgChangeRate":0.043488},{"month":4,"riseRate":0.25,"avgChangeRate":-0.134309},{"month":5,"riseRate":0.625,"avgChangeRate":0.227575},{"month":6,"riseRate":0.75,"avgChangeRate":0.084918},{"month":7,"riseRate":0.625,"avgChangeRate":0.006308},{"month":8,"riseRate":0.75,"avgChangeRate":0.170306},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.008075},{"month":10,"riseRate":0.333333,"avgChangeRate":0.02359},{"month":11,"riseRate":0.555556,"avgChangeRate":0.066668},{"month":12,"riseRate":0.625,"avgChangeRate":0.036089}],"exchange":"NASDAQ","name":"Protagonist Therapeutics Inc","nameEN":"Protagonist Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagonist Therapeutics Inc(PTGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Protagonist Therapeutics Inc(PTGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Protagonist Therapeutics Inc,PTGX,Protagonist Therapeutics Inc股票,Protagonist Therapeutics Inc股票老虎,Protagonist Therapeutics Inc股票老虎国际,Protagonist Therapeutics Inc行情,Protagonist Therapeutics Inc股票行情,Protagonist Therapeutics Inc股价,Protagonist Therapeutics Inc股市,Protagonist Therapeutics Inc股票价格,Protagonist Therapeutics Inc股票交易,Protagonist Therapeutics Inc股票购买,Protagonist Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagonist Therapeutics Inc(PTGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Protagonist Therapeutics Inc(PTGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}